RA Capital Nexus Fund, L.P. Plans to Sell Sionna Therapeutics Common Stock

RA Capital Nexus Fund, L.P., a director and 10% stockholder of Sionna Therapeutics, Inc., has filed a Form 144 indicating its intent to sell 122,271 shares of common stock. The shares were acquired on September 18, 2020, through a private transaction. The planned sale is expected to occur on October 24, 2025, with an aggregate market value of approximately $4,794,245.91. The securities are listed on the NASDAQ GM, and the sale will be facilitated by BTIG, LLC. The filing also confirms that there have been no sales of securities in the past three months.